Status:
COMPLETED
Growth Hormone Treatment in Adult Patients With Chronic Kidney Disease
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Chronic Kidney Disease
End-Stage Renal Disease
Eligibility:
All Genders
18-99 years
Phase:
PHASE2
Brief Summary
This trial is conducted in Asia, Europe, and Middle East. Adult patients with chronic kidney disease are treated with growth hormone to assess effect on nutritional status.
Eligibility Criteria
Inclusion
- ESRD patients
Exclusion
- Diabetes Mellitus
- Severe and Malignant diseases
- Patients in Intensive Care Units
Key Trial Info
Start Date :
April 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2005
Estimated Enrollment :
140 Patients enrolled
Trial Details
Trial ID
NCT00184652
Start Date
April 1 2003
End Date
September 1 2005
Last Update
January 24 2017
Active Locations (26)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Århus N, Denmark, 8200
2
Novo Nordisk Investigational Site
København Ø, Denmark, 2100
3
Novo Nordisk Investigational Site
Odense, Denmark, 5000
4
Novo Nordisk Investigational Site
Berlin, Germany, 13353